How long can you take Wegovy, and what does the guidance say?

Step 1, The titration period (months one to five): settling in before you reach the working dose

Treatment starts at 0.25 mg weekly. That first pen isn't doing the heavy lifting on weight loss; its job is helping your body adjust to semaglutide before the dose climbs. The prescriber then steps the dose upward roughly every four weeks (through 0.5 mg, 1.0 mg, 1.7 mg and finally 2.4 mg) so the titration phase alone takes around four to five months. Nausea, the most common early complaint, tends to be worst in the first few weeks after each increase and usually settles as your body adapts. Knowing this timeline helps set realistic expectations: most people haven't yet reached their therapeutic dose at the point they expect results, which is a question our prescribers hear most weeks.

For those now eligible for the newer 7.2 mg maintenance dose (approved by the MHRA in April 2026), the journey from starter dose to the highest level takes correspondingly longer. The full picture of when Wegovy starts working is worth reading before you assume the first few weeks are representative.

Step 2, The active treatment phase (months five to twenty-four on the NHS pathway): where the evidence sits

Once you're on the maintenance dose, weight loss typically continues for several months before plateauing. The STEP 1 trial, published in the New England Journal of Medicine, followed adults with obesity over 68 weeks and recorded an average body-weight reduction of around 15% at 2.4 mg weekly alongside lifestyle changes. Those results came with continued treatment throughout; the losses didn't arrive in the first couple of months and then stop.

For NHS patients, NICE's guidance on semaglutide (TA875) specifies a maximum of two years, used within a specialist weight management service that provides dietary, activity and behavioural support alongside the medicine. If you've not achieved at least 5% weight loss after six months at the highest tolerated dose, the guidance advises stopping and reviewing your options.

Private treatment has no equivalent two-year ceiling written into the licence, but a responsible prescriber will review your progress at every repeat, weigh the ongoing benefits against any risks, and advise accordingly. Duration is always an individual clinical decision, not a fixed rule. You can read more about how long you can be on Wegovy across different circumstances, or explore how long Wegovy use is supported by the evidence.

Step 3, The stopping question: what happens when Wegovy ends

This is the part most people wish someone had mentioned earlier. Semaglutide acts on the GLP-1 receptors involved in appetite regulation and gastric emptying; when you stop, those effects stop too. Multiple studies, including extension data from the STEP programme, show that a significant proportion of weight lost during treatment returns within a year of stopping. That isn't a failure of the medicine, it reflects the underlying biology of obesity as a chronic condition, not a fixed problem that gets permanently solved.

Some people cycle off after two years and maintain their results well with sustained lifestyle changes. Others find that weight returns and opt to restart treatment, which is a conversation to have with your prescriber rather than a decision to make alone. The broader evidence on long-term semaglutide use covers this in more depth. If cost plays into your thinking about duration, the Wegovy price comparison gives an honest view of what private treatment costs monthly.

Step 4, Planning ahead: what a clinical review should cover before you stop or continue

Whether you're approaching the two-year mark, considering a break, or wondering whether you've been on treatment long enough, a structured clinical review matters. A prescriber should look at your total weight change, any weight-related health conditions that may have improved or resolved, your current lifestyle habits, and whether the risks of continuing outweigh the benefits. Stopping abruptly isn't dangerous in the way it would be with some medicines, but it does mean losing the appetite-regulating effect quickly.

For people on semaglutide for semaglutide's other licensed uses (cardiovascular risk reduction, or the newly approved MASH indication from July 2026), duration guidance differs and is outside the scope of a weight-management discussion. If you'd like a prescriber to review where you are in your treatment, our free consultation is the starting point. You can also learn more about Wegovy and how it works, or read a broader overview of weight-loss treatment options at nume.